BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27914130)

  • 1. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
    Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
    J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
    Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
    Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
    Amaki-Takao M; Yamaguchi T; Natsume S; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Miyaki M
    Oncology; 2016; 91(3):162-70. PubMed ID: 27404270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How should BRAF V600E-mutated colorectal cancer be treated?
    Kopetz S
    Clin Adv Hematol Oncol; 2018 May; 16(5):333-335. PubMed ID: 29851929
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome.
    Tsai JH; Liau JY; Lin YL; Tseng LH; Lin LI; Yeh KH; Jeng YM
    J Clin Pathol; 2016 Apr; 69(4):319-25. PubMed ID: 26500331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
    Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.
    Rhee YY; Kim MJ; Bae JM; Koh JM; Cho NY; Juhnn YS; Kim D; Kang GH
    Ann Surg Oncol; 2012 Oct; 19(11):3441-8. PubMed ID: 22618722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.
    Digiacomo N; Bolzacchini E; Veronesi G; Cerutti R; Sahnane N; Pinotti G; Bregni M; Artale S; Verusio C; Crivelli F; Capella C; Sessa F; Furlan D
    Clin Colorectal Cancer; 2019 Jun; 18(2):e251-e260. PubMed ID: 30638691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.
    Markovic S; Antic J; Dragicevic N; Hamelin R; Krivokapic Z
    J Mol Histol; 2012 Apr; 43(2):137-43. PubMed ID: 22210186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
    Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
    Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.